Inhibition of PLK4 might enhance the anti‐tumour effect of bortezomib on glioblastoma via PTEN/PI3K/AKT/mTOR signalling pathway

Glioblastoma (GBM) is one of the most common aggressive cancers of the central nervous system in adults with a high mortality rate. Bortezomib is a boronic acid–based potent proteasome inhibitor that has been actively studied for its anti‐tumour effects through inhibition of the proteasome. The prot...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing, Ren, Dengpeng, Sun, Yan, Xu, Chao, Wang, Chunhong, Cheng, Rui, Wang, Lina, Jia, Guijun, Ren, Jinrui, Ma, Jiuhong, Tu, Yue, Ji, Hongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171416/
https://www.ncbi.nlm.nih.gov/pubmed/32126150
http://dx.doi.org/10.1111/jcmm.14996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171416/
https://www.ncbi.nlm.nih.gov/pubmed/32126150
http://dx.doi.org/10.1111/jcmm.14996

Ejemplares similares